AzurRx BioPharma Inc. (NASDAQ: AZRX) stock falls by 8.93% at last check during the current market trading. Related to this decline in AZRX stock price, there is no recent news available. AzurRx BioPharma is a biopharmaceutical clinical-stage organization that specializes in developing targeted, non-systemic treatments for gastrointestinal diseases. AZRX has a three-good GI resource pipeline. The primary diagnostic candidate in patients with cystic fibrosis and chronic pancreatitis is MS1819 which is a recombinant lipase for the cure of exocrine pancreatic insufficiency.
Recent Past Development
On 15 April 2021, James Sapirstein, CEO and Chairman, sent a letter to its shareholders outlining the accomplishments of AZRX in the first and last quarter of 2021 and recent weeks. In his letter, he mentioned that AzurRx kicked off 2021 with the announcement of a game-changing in-licensing agreement with First Wave Bio, which introduced a new asset, patented formulations of micronized niclosamide, to its clinical-stage pipeline, along with 2 additional therapeutic indications for COVID-19 GI infections and immune checkpoint inhibitor-associated colitis (ICI-AC).
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
He went on to say that he is pleased to announce that both niclosamide programs are on pace to begin in the clinic. AZRX announced the launch of RESERVOIR, a Phase 2 (Proof of Principle) clinical trial of niclosamide for the cure of COVID-19-related gastrointestinal infections, in April 2021, and they enlisted PPD, Inc., a leading clinical research organization (CRO), to handle the Phase 1b/2a ICI-AC trial, which they expect to start in Q2 2021.
AZRX has continued to improve MS1819 as a possible therapy for exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients (CF). AZRX announced topline results from its Phase 2b OPTION 2 monotherapy test at the end of Q1 2021 and expects to announce topline data from its Phase 2 combination therapy trial combining MS1819 with the existing standard of treatment, pancreatic enzyme replacement therapy (PERT), in Q2 2021. MS1819 also has the ability to replace PERT as the gold standard treatment for EPI in patients with CF and chronic pancreatitis, according to AZRX.
Whereas,
These are just the beginning of the tale. AzurRx remains committed to its goal of developing valuable GI therapies with substantial market potential and generating value for its shareholders.